Angiodynamic Inc
ANGO
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
127.2% downsideOvervalued by 127.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $502.02 Million |
|---|---|
| Enterprise Value | $464.21 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.83 |
| Beta | 0.36 |
| Outstanding Shares | 41,596,000 |
Return
| Return on Equity | -18.11% |
|---|---|
| Return on Assets | -12.04% |
| Return on Invested Capital | -7.52% |
Valuation & Multiples
| P/E Ratio | -16.2 |
|---|---|
| PEG | -19.42 |
| Price to Sales | 1.77 |
| Price to Book Ratio | 3.09 |
| Enterprise Value to Revenue | 1.48 |
| Enterprise Value to EBIT | -31.7 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3469▲ 34.69% |
|---|---|
| Total Calls | 51,600▲ 60.75% |
| Total Puts | 17,900▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 92.64%▼ 1.19% |
|---|---|
| Total Invested | $437.38M▼ 12.06% |
| Investors Holding | 150▼ 20.00% |
ESG Score
No data
About Angiodynamic Inc
CEO: James Clemmer AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines in...
Relevant Senate Committees
This committee controls taxation (impacting corporate profitability) and critical entitlement spending, particularly Medicare pricing. Medicare reimbursement rates are a direct and vital factor for medical device adoption and revenue for AngioDynamics.
This committee directly oversees the FDA, which is the primary regulatory body for AngioDynamics' medical devices, dictating product approval, safety standards, and market access.